Changes in Airway Sampling and <i>Pseudomonas aeruginosa</i> Isolation after the Introduction of Elexacaftor/Tezacaftor/Ivacaftor
Introduction of ETI coincides with reduced sample provision pppy; a minority of patients now meet Standards of Care (four or more samples pppy), challenging the use of current chronic infection definitions. Use of ETI, even in those with established chronic Pa and mucoid phenotype, coincides with reduced Pa isolation frequency/abundance.
Authors
- Jonathan Ish-Horowicz (ORCID: https://orcid.org/0000-0002-5386-6620)
- Dominic Fenn (ORCID: https://orcid.org/0000-0001-7904-8135)
- J. King (ORCID: https://orcid.org/0000-0002-4384-1999)
- M. Mossop (ORCID: https://orcid.org/0000-0003-3852-6289)
- Jane C. Davies (ORCID: https://orcid.org/0000-0003-3506-1199)
- Newara Ramadan (ORCID: https://orcid.org/0000-0003-3628-559X)
- Mark Rosenthal (ORCID: https://orcid.org/0000-0001-5535-9684)
Institutions
- Royal Brompton Hospital (GB)
- Lung Institute (US)
- Imperial College London (GB)
Publication Details
- Journal
- Annals of the American Thoracic Society
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1513/annalsats.202503-278oc
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00